John Radford is Professor of Medical Oncology at the University of Manchester and Director of Research at the Christie NHS Foundation Trust, both partners in the Manchester Cancer Research Centre (MCRC). His research interests are focused on developing and testing new ways of treating lymphoma and monitoring the effectiveness of these using novel biomarkers. He is also interested in studying the late effects of chemotherapy on fertility, heart function and the risk of second cancers.
John chairs the Manchester Lymphoma Group, is immediate past chair of the UK National Cancer Research Institute (NCRI) Lymphoma Clinical Studies Group and is chief investigator for several national/international trials. He has advised the Parliamentary Ombudsman, NICE and the National Horizon Scanning Centre and is a member of the Editorial Board of the Journal of Clinical Oncology. He became honorary President of Lymphoma Action in September 2019.